» Articles » PMID: 12086237

Management of Common Arrhythmias: Part I. Supraventricular Arrhythmias

Overview
Specialty Public Health
Date 2002 Jun 28
PMID 12086237
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Family physicians frequently encounter patients with symptoms that could be related to cardiac arrhythmias, most commonly atrial fibrillation or supraventricular tachycardias. The initial management of atrial fibrillation includes ventricular rate control to provide adequate cardiac output. In patients with severely depressed cardiac output and recent-onset atrial fibrillation, immediate electrical cardioversion is the treatment of choice. Hemodynamically stable patients with atrial fibrillation for more than two days or for an unknown period should be assessed for the presence of atrial thrombi. If thrombi are detected on transesophageal echocardiography, anticoagulation with warfarin for a minimum of 21 days is recommended before electrical cardioversion is attempted. Patients with other supraventricular arrhythmias may be treated with adenosine, a calcium channel blocker, or a short-acting beta blocker to disrupt reentrant pathways. When initial medications are ineffective, radiofrequency ablation of ectopic sites is an increasingly popular treatment option.

Citing Articles

Sustained Supraventricular Tachycardia While in Active Phase Labor.

Gold A, Sadek M HCA Healthc J Med. 2025; 6(1):75-78.

PMID: 40071182 PMC: 11892395. DOI: 10.36518/2689-0216.1720.


Pheniramine induced supraventricular tachycardia resistant to adenosine: A case report and review.

Farah Yusuf Mohamud M, Waberi M Ann Med Surg (Lond). 2022; 78:103621.

PMID: 35600167 PMC: 9121280. DOI: 10.1016/j.amsu.2022.103621.


Continuous Blood Pressure Estimation From Electrocardiogram and Photoplethysmogram During Arrhythmias.

Liu Z, Zhou B, Li Y, Tang M, Miao F Front Physiol. 2020; 11:575407.

PMID: 33013491 PMC: 7509183. DOI: 10.3389/fphys.2020.575407.


Emerging adenosine receptor agonists.

Gao Z, Jacobson K Expert Opin Emerg Drugs. 2007; 12(3):479-92.

PMID: 17874974 PMC: 11790296. DOI: 10.1517/14728214.12.3.479.